GlucoTrack (GCTK) Q3 2024 earnings summary

Executive summary

• Focused on developing an implantable continuous glucose monitor (CBGM) for Type 1 and insulin-dependent Type 2 diabetes, with recent animal studies showing promising results and regulatory submission for first-in-human study expected to initiate in Q4 2024.

• Shifted strategy away from non-invasive earlobe device to focus on implantable CGM, with ongoing preparations for ISO13485 certification and long-term clinical trials.

• Management team strengthened with experienced hires and board members from leading diabetes and medical device companies.

Financial highlights

• Net loss for Q3 2024 was $5.1 million, up from $2.2 million in Q3 2023; net loss for the nine months ended September 30, 2024 was $12.5 million, compared to $4.7 million for the same period in 2023.

• Research and development expenses rose to $2.1 million in Q3 2024 (from $1.7 million in Q3 2023) and $7.8 million for the nine months (from $3.0 million in 2023), reflecting increased product development and clinical activities.

• General and administrative expenses increased to $1.1 million in Q3 2024 (from $0.5 million in Q3 2023) and $2.6 million for the nine months (from $1.7 million in 2023).

• Finance expenses, net, were $1.9 million in Q3 2024, mainly due to $1.5 million in revaluation expenses from settlement of financial liabilities and $0.3 million in discount amortization and interest expenses.

• Cash and cash equivalents as of September 30, 2024 were $346,000, with an accumulated deficit of $122.7 million.

Outlook and guidance

• Expects research and development expenses to increase in 2025 and beyond due to hiring and clinical trials for the Glucotrack CBGM.

• Cash on hand and expected proceeds from a November 2024 public offering are insufficient to fund operations for the next twelve months; additional financing will be required.

• Management is pursuing further equity and/or debt financing and may adjust R&D spending based on available resources.